Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals, Inc. (ANIP) submitted a Form 144 notifying the proposed sale of 9,000 shares of common stock via Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $801,450.00 for those shares and reports 21,688,772 shares outstanding for the issuer. The 9,000 shares were acquired from the issuer as restricted stock on 03/23/2022, and no securities were reported sold by the seller in the past three months. The notice includes the required representation that the selling person is not aware of undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares. The shares are scheduled for an approximate sale date of 08/15/2025 through Morgan Stanley Smith Barney LLC and carry an aggregate market value of $7,866,267.50. The filing reports 21,688,772 shares outstanding, meaning the proposed sale represents a small fraction of total shares. The 91,000 shares were acquired on 11/19/2021 in exchange for convertible preferred shares and were paid for in cash on the acquisition date. No other sales in the prior three months were reported.
ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 52,990 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $4,618,063.56, and reports 21,688,772 shares outstanding. The filer indicates the shares were acquired on 11/19/2021 via a company buyout and are being sold as a compensatory payment. The filing also lists a recent sale by the same person: 47,010 common shares sold on 08/14/2025 for gross proceeds of $4,206,603.82. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.
ANI Pharmaceuticals insider transaction: Thomas Rowland, SVP, Head - Established Brands, reported sale of 4,975 shares of ANI Pharmaceuticals, Inc. common stock on 08/12/2025 at a weighted average price of $85.71 per share. After the reported sale, the filing shows 40,794 shares beneficially owned.
The filing notes that 304 of those shares were acquired under the company's Employee Stock Purchase Plan and were exempt under Rule 16b-3. The Form 4 was submitted and signed by attorney-in-fact Meredith W. Cook on behalf of Thomas Rowland.
ANI Pharmaceuticals insider transaction: The company's President & CEO and director, Nikhil Lalwani, reported selling 56,960 shares of ANI Pharmaceuticals, Inc. (ANIP) on 08/12/2025 at a weighted average sale price of $85.93 per share. After the sale, he beneficially owns 411,219 shares, reported as directly owned.
The Form 4 was signed by attorney-in-fact Meredith W. Cook on 08/14/2025 and notes the shares were sold in multiple trades with execution prices ranging from $84.40 to $87.47. No derivative transactions or other securities classes are reported.
Ori Gutwerg, listed as SVP, Generics at ANI Pharmaceuticals (ANIP), reported a sale of 5,873 shares of ANI common stock on 08/12/2025. The shares were sold in multiple trades at prices ranging from $86.50 to $86.79, with a disclosed weighted average sale price of $86.53. After the transactions, the reporting person beneficially owned 84,024 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact for the reporting person.
Meredith W. Cook, Sr. VP, General Counsel & Sec. of ANI Pharmaceuticals (ANIP), reported the sale of 400 shares of the company’s common stock on 08/13/2025 at a price of $88.87 per share. After the sale, Ms. Cook beneficially owns 76,474 shares directly. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on September 17, 2024, indicating the transaction followed a prearranged instruction to sell. The Form 4 shows a single non-derivative disposition and lists Ms. Cook’s role and contact address with the issuer.
ANI Pharmaceuticals insider transactions: Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals (ANIP), reported transactions on 08/12/2025 that changed his beneficial ownership. He acquired 50,000 shares by exercising options at a $46.49 exercise price and simultaneously sold 50,000 shares at $86.07. After the transactions his reported beneficial ownership moved from 230,863 shares to 180,863 shares. The filing notes option vesting schedule information dating to 2017-2020 and is signed by an attorney-in-fact on Carey’s behalf.
Thomas Haughey, a director of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 19,341 shares of the company's common stock on 08/12/2025 at a weighted-average price of $85.93 per share, according to this Form 4 filing. After the sale, Haughey beneficially owned 36,521 shares. The filing indicates the shares were sold in multiple trades at prices ranging from $84.50 to $87.16, and the form was signed by attorney-in-fact Meredith W. Cook on 08/14/2025.
The report is a standard Section 16 disclosure showing an insider disposition; it provides the exact quantities, price range, and resulting beneficial ownership recorded on the form.
ANI Pharmaceuticals (ANIP) notice reports a proposed sale of 47,010 shares of common stock via Merrill Lynch on 08/14/2025 with an aggregate market value of $4,206,603.82. The shares represent part of the outstanding share count of 21,688,772. The filer states the shares were acquired on 11/19/2021 in a company buyout from ANI Pharmaceuticals and that the payment is a compensatory payment. No sales by the filer are reported in the prior three months. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.